| 8.91 0.02 (0.22%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.38 | 1-year : | 13.3 |
| Resists | First : | 9.75 | Second : | 11.38 |
| Pivot price | 8.87 |
|||
| Supports | First : | 8.56 | Second : | 7.82 |
| MAs | MA(5) : | 8.66 |
MA(20) : | 8.82 |
| MA(100) : | 7.69 |
MA(250) : | 7.9  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 40.6 |
D(3) : | 30.4 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 11.55 | Low : | 5.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NVAX ] has closed below upper band by 48.0%. Bollinger Bands are 12.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.35 - 9.39 | 9.39 - 9.43 |
| Low: | 8.76 - 8.8 | 8.8 - 8.84 |
| Close: | 8.85 - 8.91 | 8.91 - 8.98 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Tue, 14 Oct 2025
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Benzinga
Tue, 14 Oct 2025
Novavax shareholder with large stake asks company to consider selling itself - Seeking Alpha
Fri, 10 Oct 2025
Novavax Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Wed, 08 Oct 2025
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
Mon, 06 Oct 2025
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Nasdaq
Thu, 25 Sep 2025
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 162 (M) |
| Shares Float | 137 (M) |
| Held by Insiders | 8.7 (%) |
| Held by Institutions | 58.5 (%) |
| Shares Short | 43,450 (K) |
| Shares Short P.Month | 43,870 (K) |
| EPS | 2.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.23 |
| Profit Margin | 39.2 % |
| Operating Margin | 44.1 % |
| Return on Assets (ttm) | 14.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -42.5 % |
| Gross Profit (p.s.) | 3.79 |
| Sales Per Share | 6.64 |
| EBITDA (p.s.) | 2.5 |
| Qtrly Earnings Growth | -38.1 % |
| Operating Cash Flow | -631 (M) |
| Levered Free Cash Flow | -627 (M) |
| PE Ratio | 4.01 |
| PEG Ratio | 0 |
| Price to Book value | 38.73 |
| Price to Sales | 1.33 |
| Price to Cash Flow | -2.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|